173 related articles for article (PubMed ID: 29465751)
1. Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial.
Davarzani N; Hutchins GGA; West NP; Hewitt LC; Nankivell M; Cunningham D; Allum WH; Smyth E; Valeri N; Langley RE; Grabsch HI
Histopathology; 2018 Jun; 72(7):1180-1188. PubMed ID: 29465751
[TBL] [Abstract][Full Text] [Related]
2. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma.
Reece-Smith AM; Saunders JH; Soomro IN; Bowman CR; Duffy JP; Kaye PV; Welch NT; Madhusudan S; Parsons SL
Ann R Coll Surg Engl; 2017 May; 99(5):378-384. PubMed ID: 28462649
[TBL] [Abstract][Full Text] [Related]
3. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
4. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
Noble F; Lloyd MA; Turkington R; Griffiths E; O'Donovan M; O'Neill JR; Mercer S; Parsons SL; Fitzgerald RC; Underwood TJ;
Br J Surg; 2017 Dec; 104(13):1816-1828. PubMed ID: 28944954
[TBL] [Abstract][Full Text] [Related]
5. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
Smyth EC; Fassan M; Cunningham D; Allum WH; Okines AF; Lampis A; Hahne JC; Rugge M; Peckitt C; Nankivell M; Langley R; Ghidini M; Braconi C; Wotherspoon A; Grabsch HI; Valeri N
J Clin Oncol; 2016 Aug; 34(23):2721-7. PubMed ID: 27298411
[TBL] [Abstract][Full Text] [Related]
6. Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial.
Hale MD; Nankivell M; Hutchins GG; Stenning SP; Langley RE; Mueller W; West NP; Wright AI; Treanor D; Hewitt LC; Allum WH; Cunningham D; Hayden JD; Grabsch HI
Oncotarget; 2016 Nov; 7(47):77565-77575. PubMed ID: 27769054
[TBL] [Abstract][Full Text] [Related]
7. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
Sundar R; Ng A; Zouridis H; Padmanabhan N; Sheng T; Zhang S; Lee MH; Ooi WF; Qamra A; Inam I; Hewitt LC; So JB; Koh V; Nankivell MG; Langley RE; Allum WH; Cunningham D; Rozen SG; Yong WP; Grabsch HI; Tan P
Eur J Cancer; 2019 Dec; 123():48-57. PubMed ID: 31655359
[TBL] [Abstract][Full Text] [Related]
8. Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy.
Powell AGMT; Karran A; Blake P; Christian A; Roberts SA; Lewis WG
BJS Open; 2020 Aug; 4(4):593-600. PubMed ID: 32374504
[TBL] [Abstract][Full Text] [Related]
9. Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients.
Kadota T; Hatogai K; Yano T; Fujita T; Kojima T; Daiko H; Fujii S
Cancer Sci; 2018 Jun; 109(6):2046-2055. PubMed ID: 29601131
[TBL] [Abstract][Full Text] [Related]
10. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
11. Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas.
Reim D; Novotny A; Friess H; Slotta-Huspenina J; Weichert W; Ott K; Dislich B; Lorenzen S; Becker K; Langer R
J Pathol Clin Res; 2020 Oct; 6(4):263-272. PubMed ID: 32401432
[TBL] [Abstract][Full Text] [Related]
12. Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma.
Davies AR; Myoteri D; Zylstra J; Baker CR; Wulaningsih W; Van Hemelrijck M; Maisey N; Allum WH; Smyth E; Gossage JA; Lagergren J; Cunningham D; Green M;
Br J Surg; 2018 Nov; 105(12):1639-1649. PubMed ID: 30047556
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
[TBL] [Abstract][Full Text] [Related]
14. Impact of neoadjuvant chemotherapy on nodal regression and survival in oesophageal adenocarcinoma.
Evans RP; Kamarajah SK; Kunene V; Zardo D; Elshafie M; Griffiths EA
Eur J Surg Oncol; 2022 May; 48(5):1001-1010. PubMed ID: 34974947
[TBL] [Abstract][Full Text] [Related]
15. Pathological Regression of Lymph Nodes Better Predicts Long-term Survival in Esophageal Cancer Patients Undergoing Neoadjuvant Chemotherapy Followed by Surgery.
Hagi T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Morii E; Eguchi H; Doki Y
Ann Surg; 2022 Jun; 275(6):1121-1129. PubMed ID: 32910622
[TBL] [Abstract][Full Text] [Related]
16. Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.
Cha EK; Sfakianos JP; Sukhu R; Yee AM; Sjoberg DD; Bochner BH
BJU Int; 2018 Oct; 122(4):627-632. PubMed ID: 29633530
[TBL] [Abstract][Full Text] [Related]
17. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S
Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890
[TBL] [Abstract][Full Text] [Related]
18. Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology.
De Cobelli F; Giganti F; Orsenigo E; Cellina M; Esposito A; Agostini G; Albarello L; Mazza E; Ambrosi A; Socci C; Staudacher C; Del Maschio A
Eur Radiol; 2013 Aug; 23(8):2165-74. PubMed ID: 23588582
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma.
Derieux S; Svrcek M; Manela S; Lagorce-Pages C; Berger A; André T; Taieb J; Paye F; Voron T
Dig Liver Dis; 2020 Jan; 52(1):107-114. PubMed ID: 31427088
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of the Location of Lymph Node Metastases After Neoadjuvant Chemotherapy for Middle and Lower Thoracic Esophageal Cancer.
Miyata H; Sugimura K; Yamasaki M; Makino T; Tanaka K; Morii E; Omori T; Yamamoto K; Yanagimoto Y; Yano M; Nakatsuka S; Mori M; Doki Y
Ann Surg Oncol; 2019 Jan; 26(1):200-208. PubMed ID: 30374924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
